The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Open accessAbstract
Among the three human apolipoprotein E (apoE) isoforms, apoE4 increases the risk of Alzheimer's disease (AD). While transporting cholesterol is a primary function, apoE also regulates amyloid-β (Aβ) metabolism, aggregation, and deposition. Although earlier work suggests that different affinities of apoE isoforms to Aβ might account for their effects on Aβ clearance, recent studies indicate that apoE also competes with Aβ for cellular uptake through apoE receptors. Thus, several factors probably determine the variable effects apoE has on Aβ. In this Review, we examine biochemical, structural, and functional studies and propose testable models that address the complex mechanisms underlying apoE-Aβ interaction and how apoE4 may increase AD risk and also serve as a target pathway for therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As these molecules play critical roles in Aβ clearance and tau aggregation,41,42 the ε7 isoform may influence AD pathology through these pathways.”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ApoE is also a crucial factor in the development of AD (5, 6, 31, 32).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“APOE binds to cell surface receptors, such as low‐density lipoprotein receptor (LDLR), LDLR‐related protein 1 (LRP1), very low‐density lipoprotein receptor (VLDLR), and apolipoprotein E receptor 2 (APOER2 or LRP8). 2 , 14 , 15”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Since APOE regulates Aβ clearance via LDL receptors and microglia are critical for Aβ clearance, 15 we first focused on the role of IDOL in microglia.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, brain Aβ pathology is inarguably associated with APOE4 status (7).”
From APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1 (2019) · cites this paper as [7]
In the citing paper
“Apolipoprotein (apo) E4, an isoform of the APOE gene in humans, is the major genetic risk factor for late-onset familial and sporadic AD [4–8], which account for most AD cases.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [7]
In the citing paper
“Overall, it has been demonstrated, both in vivo and in vitro, that apoE plays major roles in AD pathogenesis in both an Aβ-dependent and independent manner, and different cellular sources of apoE4 may contribute in distinct ways to AD pathogenesis [4–8, 12–14, 21, 22].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,372
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Flagged first, then by citations
1 of the 166 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 626
The Role of the GABAergic System in Diseases of the Central Nervous System
Zhang, W., Xiong, B., Zhang, L.-Q., Huang, X., Yuan, X., Tian, Y., & Tian, X. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.06.037 · Cited by 97
Relationship between amyloid and tau levels and its impact on tau spreading
Doré, V., Krishnadas, N., Bourgeat, P., Huang, K., Li, S., Burnham, S. C., Masters, C. L., Fripp, J., Villemagne, V. L., & Rowe, C. C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05191-9 · Cited by 93
Calderón‐Garcidueñas, L., Mora-Tiscareño, A., Franco-Lira, M., Hongtu Zhu, B., Lu, Z., Solorio, E., Torres‐Jardón, R., & D’Angiulli, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142685 · Cited by 92
Tachibana, M., Yamazaki, Y., Liu, C., Bu, G., & Kanekiyo, T. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.023 · Cited by 92
Self-citationVps35-dependent recycling of Trem2 regulates microglial function
Yin, J., Liu, X., He, Q., Zhou, L., Yuan, Z., & Zhao, S. (2016) · Traffic · doi:10.1111/tra.12451 · Cited by 90
Flores‐Bellver, M., Mighty, J., Aparicio‐Domingo, S., Li, K. V., Shi, C., Zhou, J., Cobb, H., McGrath, P. S., Michelis, G., Lenhart, P., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12165 · Cited by 89
The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
Yamazaki, Y., Shinohara, M., Yamazaki, A., Ren, Y., Asmann, Y. W., Kanekiyo, T., & Bu, G. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313169 · Cited by 89
Self-citationRevisiting the critical roles of reactive astrocytes in neurodegeneration
Qian, K., Jiang, X., Liu, Z., Zhang, J., Fu, P. F., Su, Y., Brazhe, N. A., Liu, D., & Zhu, L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02061-8 · Cited by 101
Lim, Y. Y., Kalinowski, P., Pietrzak, R. H., Laws, S. M., Burnham, S. C., Ames, D. J., Villemagne, V. L., Fowler, C. J., Rainey‐Smith, S. R., Martins, R. N., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4325 · Cited by 87
Potential Neuroprotective Effects of Adiponectin in Alzheimer’s Disease
Ng, R. C.-L., & Chan, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030592 · Cited by 84
Calderón‐Garcidueñas, L., Jewells, V. L., Galaz-Montoya, C. I., van Zundert, B., Pérez-Calatayud, Á. A., Ascencio-Ferrel, E., Valencia‐Salazar, G., Sandoval-Cano, M., Carlos, E., Solorio, E., et al. (2016) · Environmental Research · doi:10.1016/j.envres.2016.06.026 · Cited by 82
Ma, Z., Jiang, W., & Zhang, E. E. (2016) · Scientific Reports · doi:10.1038/srep36035 · Cited by 79
Clusterin levels are increased in A lzheimer's disease and influence the regional distribution of Aβ
Miners, J. S., Clarke, P., & Love, S. (2016) · Brain Pathology · doi:10.1111/bpa.12392 · Cited by 83
Qian, Z., Qin, J., Lai, Y., Zhang, C., & Zhang, X. (2023) · Biomolecules · doi:10.3390/biom13040692 · Cited by 81
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Sadikki, H., Fayossé, A., Cognat, E., Sabia, S., Engelborghs, S., Wallon, D., Alexopoulos, P., Blennow, K., Zetterberg, H., Parnetti, L., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1003289 · Cited by 87
Bester, J., Soma, P., Kell, D. B., & Pretorius, E. (2015) · Oncotarget · doi:10.18632/oncotarget.6074 · Cited by 77
Towards Understanding the Roles of Heparan Sulfate Proteoglycans in Alzheimer’s Disease
Zhang, G.-L., Zhang, X., Wang, X., & Li, J. (2014) · BioMed Research International · doi:10.1155/2014/516028 · Cited by 80
Perkins, M., Wolf, A. B., Chavira, B., Shonebarger, D., Meckel, J. P., Leung, L., Ballina, L. E., Ly, S., Saini, A., Jones, T. B., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151205 · Cited by 79
Zhao, J., Fu, Y., Liu, C.-C., Shinohara, M., Nielsen, H. M., Dong, Q., Kanekiyo, T., & Bu, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526095 · Cited by 67
Self-citationFu, Y., Zhao, J., Atagi, Y., Nielsen, H. M., Liu, C.-C., Zheng, H., Shinohara, M., Kanekiyo, T., & Bu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0099-y · Cited by 69
Self-citationGadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 71
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S. S., Agarwal, R., Taneja, V., & Kukreti, R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9390-0 · Cited by 71
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice
Fitz, N. F., Wolfe, C. M., Playso, B. E., Biedrzycki, R. J., Lu, Y., Nam, K. N., Lefterov, I., & Koldamova, R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00394-4 · Cited by 68
Nikitidou, E., Khoonsari, P. E., Shevchenko, G., Ingelsson, M., Kultima, K., & Erlandsson, A. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170278 · Cited by 68
Insel, P. S., Hansson, O., & Mattsson-Carlgren, N. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3780 · Cited by 68
Puangmalai, N., Sengupta, U., Bhatt, N., Gaikwad, S., Montalbano, M., Bhuyan, A., Garcia, S., McAllen, S., Sonawane, M., Jerez, C., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101766 · Cited by 68
Modeling Late-Onset Sporadic Alzheimer’s Disease through BMI1 Deficiency
Flamier, A., El Hajjar, J., Adjaye, J., Fernandes, K. J., Abdouh, M., & Bernier, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.097 · Cited by 65
microRNAs in Neurodegeneration: Current Findings and Potential Impacts
Sharma, S., & Lu, H. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000420 · Cited by 67
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735524 · Cited by 66
Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J. S., Cho, M., & Hampel, H. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 70
Association of Smoking and Alcohol Drinking with Dementia Risk Among Elderly Men in China
Zhou, S., Zhou, R., Zhong, T., Li, R., Tan, J., & Zhou, H. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141001123356 · Cited by 68
Ashford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 66
Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective
Fox, M. M., Knorr, D. A., & Haptonstall, K. P. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14129 · Cited by 67
Mitigating Alzheimer’s Disease with Natural Polyphenols: A Review
Gaudreault, R., & Mousseau, N. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190315093520 · Cited by 65
Kumral, D., Schaare, H. L., Beyer, F., Reinelt, J., Uhlig, M., Liem, F., Lampe, L., Babayan, A., Reiter, A., Erbey, M., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2018.10.027 · Cited by 64
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 71
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?
Millan, M. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/mmillan · Cited by 66
Fan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 64
Panitch, R., Hu, J., Chung, J., Zhu, C., Meng, G., Xia, W., Bennett, D. A., Lunetta, K. L., Ikezu, T., Au, R., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01266-z · Cited by 59
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67
Merino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63
Chernick, D., Ortiz‐Valle, S., Jeong, A., Qu, W., & Li, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134306 · Cited by 64
Weigand, A. J., Thomas, K. R., Bangen, K. J., Eglit, G. M. L., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, F. T. A. D. N. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12173 · Cited by 59
Dubey, S. K., Munnangi, S. R., Krishna, K. V., Saha, R. N., Singhvi, G., Agrawal, M., Ajazuddin, M., Saraf, S., Saraf, S., & Alexander, A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00653-z · Cited by 64
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway
Casey, C. S., Atagi, Y., Yamazaki, Y., Shinohara, M., Tachibana, M., Fu, Y., Bu, G., & Kanekiyo, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.625251 · Cited by 63
Self-citationRole of Neuron and Glia in Alzheimer’s Disease and Associated Vascular Dysfunction
Bandyopadhyay, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.653334 · Cited by 64
Insulin mediated novel therapies for the treatment of Alzheimer's disease
Dubey, S. K., Lakshmi, K. K., Krishna, K. V., Agrawal, M., Singhvi, G., Saha, R. N., Saraf, S., Saraf, S., Shukla, R., & Alexander, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117540 · Cited by 62
Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease
Phan, T., & Malkani, R. G. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.10.001 · Cited by 66
The Oral–Gut Microbiome–Brain Axis in Cognition
Adil, N. A., Omo-erigbe, C., Yadav, H., & Jain, S. (2025) · Microorganisms · doi:10.3390/microorganisms13040814 · Cited by 65
Developing therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
A role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance
Zhang, H., Chen, W., Tan, Z., Zhang, L., Dong, Z., Cui, W., Zhao, K., Wang, H., Jing, H., Cao, R., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0250-20.2020 · Cited by 58
Winter, M., Tholey, A., Kristen, A. V., & Röcken, C. (2017) · PROTEOMICS · doi:10.1002/pmic.201700236 · Cited by 58
Raha‐Chowdhury, R., Henderson, J. W., Raha, A. A., Vuono, R., Bickerton, A., Jones, E. A., Fincham, R., Allinson, K. S. J., Holland, A. J., & Zaman, S. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181179 · Cited by 57
Liu, C., Yamazaki, Y., Heckman, M. G., Martens, Y. A., Jia, L., Yamazaki, A., Diehl, N. N., Zhao, J., Zhao, N., Deture, M. A., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12104 · Cited by 59
Self-citationPhoto-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer’s disease mice
Ozawa, S., Hori, Y., Shimizu, Y., Taniguchi, A., Suzuki, T., Wang, W., Chiu, Y. W., Koike, R., Yokoshima, S., Fukuyama, T., et al. (2021) · Brain · doi:10.1093/brain/awab058 · Cited by 58
Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1
Tachibana, M., Shinohara, M., Yamazaki, Y., Liu, C., Rogers, J. T., Bu, G., & Kanekiyo, T. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.12.003 · Cited by 57
Self-citationCentral nervous system cholesterol metabolism in health and disease
Ho, W. Y., Hartmann, H., & Ling, S. (2022) · IUBMB Life · doi:10.1002/iub.2662 · Cited by 58
Dong, H. K., Gim, J., Yeo, S. H., & Kim, H. (2016) · Gene · doi:10.1016/j.gene.2016.10.022 · Cited by 57
“Disease modifying nutricals” for multiple sclerosis
Schmitz, K., Barthelmes, J., Stolz, L., Beyer, S., Diehl, O., & Tegeder, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.015 · Cited by 55
Li, X., Montine, K. S., Keene, C. D., & Montine, T. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262683 · Cited by 54
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease
Rohn, T. T., Kim, N., Isho, N. F., & Mack, J. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000439 · Cited by 58
Bilousova, T. V., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Hatami, A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 57
Expression of BC1 Impairs Spatial Learning and Memory in Alzheimer’s Disease Via APP Translation
Zhang, T., Pang, P., Fang, Z., Guo, Y., Li, H., Li, X., Tian, T., Yang, X., Chen, W., Shu, S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0820-z · Cited by 52
Interactions of Amyloid-β with Membrane Proteins
Wiatrak, B., Piasny, J., Kuźniarski, A., & Gąsiorowski, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116075 · Cited by 53
The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease
Xia, M., Cheng, X., Yi, R., Gao, D., & Xiong, J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8994-0 · Cited by 53
Robert, J., Button, E. B., Stukas, S. K., Boyce, G. K., Gibbs, E., Cowan, C. M., Gilmour, M., Cheng, W. H., Soo, S. K., Yuen, B., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0201-0 · Cited by 54
Chernick, D., Ortiz‐Valle, S., Jeong, A., Swaminathan, S. K., Kandimalla, K. K., Rebeck, G. W., & Li, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14554 · Cited by 51
Apolipoprotein E regulates mitochondrial function through the PGC-1α-sirtuin 3 pathway
Yin, J., Nielsen, M., Carcione, T., Li, S., & Shi, J. (2019) · Aging · doi:10.18632/aging.102516 · Cited by 52
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Almgren, H., Camacho, M., Hanganu, A., Kibreab, M., Camicioli, R. M., Ismail, Z., Forkert, N. D., & Monchi, O. (2023) · Scientific Reports · doi:10.1038/s41598-023-37644-6 · Cited by 52
Genetic Influences in Traumatic Brain Injury
Laskowitz, D., & Grant, G. A. (2015) · CRC Press eBooks · doi:10.1201/b18959-14 · Cited by 54
Developmental roles of microglia: A window into mechanisms of disease
Anderson, S., & Vetter, M. L. (2018) · Developmental Dynamics · doi:10.1002/dvdy.1 · Cited by 53
Adaptive immune changes associate with clinical progression of Alzheimer’s disease
van Olst, L., Kamermans, A., Halters, S., van der Pol, S. M. A., Rodríguez, E., Verberk, I. M. W., Verberk, S. G. S., Wessels, D. W. R., Rodriguez-Mogeda, C., Verhoeff, J., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00726-8 · Cited by 61
Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults
Chiu, M., Fan, L., Chen, T., Chen, Y., Chieh, J.-J., & Horng, H. E. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00051 · Cited by 48
Fitz, N. F., Nam, K. N., Koldamova, R. P., & Lefterov, I. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14668 · Cited by 52
Chai, A. B., Hartz, A. M. S., Gao, X., Yang, A., Callaghan, R., & Gelissen, I. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010246 · Cited by 51
Choi, J., Gao, J., Kim, J., Hong, C., Kim, J., & Tontonoz, P. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1904 · Cited by 49
Hu, M. L., Quinn, J., & Xue, K. (2021) · Life · doi:10.3390/life11070635 · Cited by 51
Advances in high-density lipoprotein physiology: surprises, overturns, and promises
Constantinou, C., Karavia, E. A., Xepapadaki, E., Πετροπούλου, Π.-Ι., Παπακώστα, Ε., Karavyraki, M., Zvintzou, E., Theodoropoulos, V., Filou, S., Hatziri, A., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00429.2015 · Cited by 48
Current status and future prospects of stem cell therapy in Alzheimer’s disease
Fu, X., Zeng, L., Zhang, F., Jiang, J., Zhang, J.-T., & Niu, H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.265544 · Cited by 53
Calderón‐Garcidueñas, L., Mora-Tiscareño, A., Melo-Sánchez, G., Rodríguez-Díaz, J., Torres‐Jardón, R., Styner, M. A., Mukherjee, P. S., Lin, W., & Jewells, V. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150415 · Cited by 50
Madhu, P., & Mukhopadhyay, S. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30141 · Cited by 53
Raulin, A.-C., Kraft, L., Al-Hilaly, Y. K., Xue, W.-F., McGeehan, J. E., Atack, J. R., & Serpell, L. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.019 · Cited by 47
Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease
Theendakara, V. P., Bredesen, D. E., & Rao, R. V. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.07.002 · Cited by 45
Alcendor, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051490 · Cited by 47
Ren, X., Yao, L., Wang, Y., Mei, L., & Xiong, W.-C. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02422-0 · Cited by 42
Dumas, M., & Davidovic, L. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9578-5 · Cited by 49
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET
Matsuda, H., Shigemoto, Y., & Sato, N. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00867-7 · Cited by 50
Schmitz, T. W., Soreq, H., Poirier, J., & Spreng, R. N. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1184-19.2019 · Cited by 47
Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon?
Hartmann, H., Ho, W. Y., Chang, J., & Ling, S. (2021) · FEBS Journal · doi:10.1111/febs.16175 · Cited by 45
The multifaceted role of WNT signaling in Alzheimer’s disease onset and age-related progression.
Kostes, W. W., & Brafman, D. A. (2023) · Cells · doi:10.3390/cells12081204 · Cited by 43
Takasugi, M., Nonaka, Y., Takemura, K., Yoshida, Y., Stein, F., Schwarz, J., Adachi, J., Satoh, J., Ito, S., Tombline, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52845-x · Cited by 57
Payton, A., Sindrewicz, P., Pessoa, V., Platt, H., Horan, M. A., Ollier, W., Bubb, V. J., Pendleton, N., & Quinn, J. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.017 · Cited by 44
Hajjar, J. E., Chatoo, W., Hanna, R., Nkanza, P., Tétreault, N., Tse, Y. C., Wong, T. P., Abdouh, M., & Bernier, G. (2019) · Scientific Reports · doi:10.1038/s41598-018-37444-3 · Cited by 46
Diabetes Mellitus Increases Risk of Incident Dementia in APOE ɛ 4 Carriers: A Meta-Analysis
Li, L., Cavuoto, M. G., Biddiscombe, K. J., & Pike, K. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191068 · Cited by 44
Damotte, V., van der Lee, S. J., Chouraki, V. A., Grenier‐Boley, B., Simino, J. M., Adams, H. H. H., Tosto, G., White, C. C., Terzikhan, N., Cruchaga, C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12333 · Cited by 40
Metadata
- Authors
- Kanekiyo, T., Xu, H., & Bu, G.
- Affiliations
- Mayo Clinic (US)
- Xiamen University (CN)
- Corresponding author
- Bu, Guojun
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 81
- Issue
- 4
- Pages
- 740-754
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC3983361
- OpenAlex
- W2051765035
- Cited by
- 608
- References
- 166
- Citations by year
- 2026: 33 · 2025: 64 · 2024: 59 · 2023: 48 · 2022: 38 · 2021: 63 · 2020: 55 · 2019: 48 · 2018: 42 · 2017: 48 · 2016: 42 · 2015: 43 · 2014: 24
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- Mayo Clinic
- National Institutes of Health
- National Institute on Aging (P01AG030128, R01AG044420, R01AG027924, R01AG021173, R01AG031784, RF1AG046205, R01AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (R01NS046673, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, amyloid-beta, Alzheimer's disease, amyloid-beta clearance, apoE receptors, APOE isoforms, amyloid-beta aggregation, cholesterol transport, disease risk, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Humans, Neurons, Risk Factors, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
